Marshall Wace
ALXN

Marshall Wace’s Alexion Pharmaceuticals ALXN Stock Holding History

Marshall Wace’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-131,070
Closed -$24.1M – 3669
2021
Q2 		$24.1M Sell
131,070
-225,196
-63% -$38.7M 0.11% 200
2021
Q1 		$54.5M Buy
356,266
+189,797
+114% +$29.4M 0.25% 71
2020
Q4 		$26M Buy
166,469
+117,008
+237% +$15M 0.14% 147
2020
Q3 		$5.66M Sell
49,461
-267,823
-84% -$28.9M 0.04% 477
2020
Q2 		$35.6M Buy
317,284
+207,469
+189% +$22M 0.25% 88
2020
Q1 		$9.86M Buy
109,815
+1,582
+1% +$155K 0.1% 215
2019
Q4 		$11.7M Buy
108,233
+18,250
+20% +$1.95M 0.08% 287
2019
Q3 		$8.81M Sell
89,983
-88,637
-50% -$9.99M 0.07% 327
2019
Q2 		$23.4M Buy
178,620
+117,490
+192% +$15.1M 0.19% 107
2019
Q1 		$8.26M Buy
61,130
+33,871
+124% +$4.21M 0.08% 313
2018
Q4 		$2.65M Buy
27,259
+21,068
+340% +$2.49M 0.03% 658
2018
Q3 		$861K Sell
6,191
-223,466
-97% -$28M 0.01% 839
2018
Q2 		$28.5M Buy
229,657
+216,380
+1,630% +$25.3M 0.43% 60
2018
Q1 		$1.48M Buy
+13,277
New +$1.59M 0.06% 229
2017
Q4 		– Sell
-2,973
Closed -$416K – 505
2017
Q3 		$416K Sell
2,973
-531
-15% -$72.1K 0.02% 291
2017
Q2 		$427K Sell
3,504
-15,632
-82% -$1.82M 0.02% 253
2017
Q1 		$2.31M Sell
19,136
-79,196
-81% -$10.2M 0.11% 127
2016
Q4 		$12M Sell
98,332
-329,362
-77% -$40.3M 0.08% 290
2016
Q3 		$52.4M Buy
427,694
+342,472
+402% +$44.1M 0.37% 65
2016
Q2 		$9.95M Buy
85,222
+72,741
+583% +$10.3M 0.08% 250
2016
Q1 		$1.74M Sell
12,481
-39,248
-76% -$5.76M 0.02% 590
2015
Q4 		$9.87M Buy
+51,729
New +$9.04M 0.09% 227
2015
Q3 		– Sell
-10,671
Closed -$1.93M – 1110
2015
Q2 		$1.93M Sell
10,671
-233,306
-96% -$40.3M 0.03% 483
2015
Q1 		$42.3M Buy
243,977
+82,215
+51% +$14.9M 0.55% 37
2014
Q4 		$29.9M Sell
161,762
-53,922
-25% -$9.99M 0.4% 64
2014
Q3 		$35.8M Buy
215,684
+162,413
+305% +$26.7M 0.52% 43
2014
Q2 		$8.32M Sell
53,271
-8,299
-13% -$1.31M 0.12% 194
2014
Q1 		$9.37M Buy
+61,570
New +$9.79M 0.17% 164

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Marshall Wace's ALXN Position: Q3 2021 in Review

Marshall Wace sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 131,070 shares — an estimated $24.1M sold.

Marshall Wace first reported a position in ALXN in Q1 2014 and held it in 28 quarters. The position peaked at $54.5M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Marshall Wace reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace sold 131,070 Alexion Pharmaceuticals shares in Q3 2021, an estimated $24.1M.
  • Marshall Wace first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 28 quarters.
  • Marshall Wace's Alexion Pharmaceuticals position peaked at $54.5M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.